Drug intelligence / Profile preview

KC5827

Development stage: Preclinical
Lead developer: Beijing Konruns Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KC5827 is an investigational oral small-molecule agonist of the glucagon-like peptide 1 receptor (GLP-1R), developed by Beijing Kangchen Biological Technology (Konruns). It is being developed for the treatment of metabolic diseases, specifically obesity and weight loss. As a small-molecule GLP-1R agonist, it is designed to provide a more convenient oral alternative to the injectable peptide-based GLP-1 therapies currently available. The drug is currently in the IND-enabling stage of development.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on KC5827.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KC5827.

Explore the full profile